Thoracic-Oncology Unit 1st, Lung Diseases Department, San Camillo-Forlanini High Specialization Hospitals, Rome, Italy.
Oncology. 2009;77 Suppl 1:103-12. doi: 10.1159/000258502. Epub 2010 Feb 2.
Lung cancer is the leading cause of cancer deaths worldwide. Novel targeted therapies based on specific molecular and biological characteristics of lung cancer have emerged as a new treatment paradigm. The current globally accepted standard of treatment for advanced non-small-cell lung cancer (NSCLC) is platinum-based combination therapy. Recently, several ongoing phase I and II trials with new drugs in NSCLC have been registered, such as sorafenib, sunitinib, mTOR inhibitors and ASA404. The optimal use of new agents is more likely in combination with standard cytotoxic or other targeted agents. Further investigations into adverse events with targeted therapy are urgently needed as these impact an increasing number of patients.
肺癌是全球癌症死亡的主要原因。基于肺癌特定分子和生物学特征的新型靶向治疗已经成为一种新的治疗范例。目前，全球公认的晚期非小细胞肺癌（NSCLC）的标准治疗方法是铂类联合化疗。最近，几项新药物治疗 NSCLC 的 I 期和 II 期临床试验已经注册，如索拉非尼、舒尼替尼、mTOR 抑制剂和 ASA404。新型药物与标准细胞毒性药物或其他靶向药物联合使用的效果可能更好。由于靶向治疗的不良反应影响越来越多的患者，因此迫切需要进一步研究这些不良反应。
